Pharmacogenetics: Anti-TNF therapy in RA--towards personalized medicine?

Cornelis L Verweij

Abstract readComment

In one paragraph

Article in Nature reviews. Rheumatology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it

0cells of the map it votes in

6citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

Identification of pathological RA endotypes using blood-based biomarkers reflecting tissue metabolism. A retrospective and explorative analysis of two phase III RA studies.PloS one · 2019
Trial
Defining response to TNF-inhibitors in rheumatoid arthritis: the negative impact of anti-TNF cycling and the need for a personalized medicine approach to identify primary non-responders.Clinical rheumatology · 2019
Review
Gene expression analysis of vascular pathophysiology related to anti-TNF treatment in rheumatoid arthritis.Arthritis research & therapy · 2019
Article
Influence of NKG2D Genetic Variants on Response to Anti-TNF Agents in Patients with Rheumatoid Arthritis.Genes · 2018
Article
Effect of Fcγ-receptor 3a (RMD open · 2017
Article
Pharmacogenetics and pharmacogenomics in rheumatology.Immunologic research · 2013
Review

4 · The record

Corrections and comments

Comment on
Genome-wide association study of genetic predictors of anti-tumor necrosis factor treatment efficacy in rheumatoid arthritis identifies associations with polymorphisms at seven loci.2011

5 · Who and what money

Authors and funding

1 author.

Cornelis L VerweijDepartments of Pathology and Rheumatology, Section of Inflammatory Disease Profiling, VU University Medical Center, Amsterdam, The Netherlands. c.verweij@vumc.nl

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A substantial proportion of patients with rheumatoid arthritis do not respond to tumor necrosis factor blocking therapy. Results of a large genome-wide association study demonstrate evidence of novel genetic factors that determine response to treatment, which could provide a basis for individualizing therapy.

Indexed as

Adaptor Proteins, Signal TransducingArthritis, RheumatoidCell Adhesion MoleculesHumansNeoplasm ProteinsPharmacogeneticsPolymorphism, Single NucleotidePrecision MedicineTrans-ActivatorsTreatment OutcomeTumor Necrosis Factor-alphaAdaptor Proteins, Signal TransducingCell Adhesion MoleculesEYA4 protein, humanNeoplasm ProteinsPDZD2 protein, humanTrans-ActivatorsTumor Necrosis Factor-alpha

Identifiers

PMID21304506

DOI10.1038/nrrheum.2011.13

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.